OncoTherapy Science, Inc.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
OncoTherapy Science, Inc. made a loss over the last year. OncoTherapy Science, Inc. owes ¥0.09 for every ¥1 it owns. OncoTherapy Science, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
LossOncoTherapy Science, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.24The share price is 3.24 times OncoTherapy Science, Inc.'s book value per share, higher than 81% of Healthcare companies in Japan.
Market cap
¥6.9 BThe total market value of all of OncoTherapy Science, Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥2.1 BWhat OncoTherapy Science, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥5.25Net worth divided by the number of shares. The share price of ¥17.00 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
-51.6%OncoTherapy Science, Inc. lost 51.6% of its shareholders' money over the last year, lower than 87% of Healthcare companies in Japan.
Owes vs Owns
0.09×OncoTherapy Science, Inc. owes ¥0.09 for every ¥1 it owns (low), lower than 93% of Healthcare companies in Japan.
Dividend yield
NoneOncoTherapy Science, Inc. does not currently pay a dividend.
Revenue growth
+8%Revenue rose 8% in the year to Mar 2026, and shrank 11% a year on average over 3 years.
Profit growth
LossOncoTherapy Science, Inc. made a loss in each of the last two years.
Profit margin
-112.6%OncoTherapy Science, Inc. lost ¥113 for every ¥100 of revenue.
Interest cover
Not coveredOncoTherapy Science, Inc.'s operating profit did not cover its interest costs in the year to Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For OncoTherapy Science, Inc.: ¥6.9 B ÷ ¥2.1 B (31 Mar 2026) = 3.2.
What is OncoTherapy Science, Inc.'s return on equity?
OncoTherapy Science, Inc. lost 51.6% of its shareholders' money over the last year, lower than 87% of Healthcare companies in Japan.
How much does OncoTherapy Science, Inc. owe compared with what it owns?
OncoTherapy Science, Inc. owes ¥0.09 for every ¥1 it owns (low), lower than 93% of Healthcare companies in Japan.
Does OncoTherapy Science, Inc. pay a dividend?
No. OncoTherapy Science, Inc. does not currently pay a dividend.
Is OncoTherapy Science, Inc.'s revenue growing?
Revenue rose 8% in the year to Mar 2026, and shrank 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.